EyePoint Investor Relations

EyePoint is a clinical-stage biotech company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases. The Company's lead product candidate, DURAVYU™ (vorolanib intravitreal insert) is presently in Phase 3 global, pivotal clinical trials for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).